NCE-1 Intelligence & Market Opportunity

Aqneursa

Levacetylleucine

Neuroprotective

Oral Suspension

Aqneursa is an oral granule formulation for patients aged 4 years and older with Niemann‑Pick disease type C. It improves neurological symptoms like coordination and balance by enhancing mitochondrial and lysosomal function and reducing cholesterol buildup in nerve cells.

Approval Date

24-Sep-24

NCE-1 Date

24-Sep-28

NCE Date

24-Sep-29

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Levacetylleucine

Innovator

INTRABIO INC

Dosage Form

Oral Suspension

Strength

1 gm/packet

Therapeutic Category

Neuroprotective

Usage

To treat Niemann-Pick disease type C

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.